Question 1

What is the current share price of Marksans Pharma Ltd (MARKSANS)?

Accepted Answer

The current share price of Marksans Pharma Ltd (MARKSANS) is ₹256.7. Today, the stock has gained by ₹6.87 (2.75%), trading in a range of ₹252.1 to ₹260. The stock opened at ₹253 with a trading volume of 6,93,785 shares.

Question 2

Is Marksans Pharma Ltd stock a good investment for long-term?

Accepted Answer

Marksans Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,504.47 crores, P/E ratio of 22.83, ROE of 7.32%, and ROCE of 20.00%. The dividend yield stands at 0.44%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

Question 3

What is the 52-week high and low price of Marksans Pharma Ltd stock?

Accepted Answer

The 52-week high price of Marksans Pharma Ltd (MARKSANS) is ₹270.6, while the 52-week low is ₹155. Currently trading at ₹256.7, the stock is 88.0% away from its 52-week low and 5.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

Question 4

Should I buy Marksans Pharma Ltd stock at the current price?

Accepted Answer

Whether to buy Marksans Pharma Ltd stock at ₹256.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 22.83 and P/B ratio of N/A. Today's performance shows a gain of 2.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

Question 5

What is the dividend yield of Marksans Pharma Ltd and when is the next dividend?

Accepted Answer

Marksans Pharma Ltd offers a dividend yield of 0.44%, which means for every ₹100 invested at the current price of ₹256.7, you can expect to receive approximately ₹0.44 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

Question 6

What are the key financial ratios and metrics of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd's key financial metrics include: P/E Ratio: 22.83, P/B Ratio: N/A, ROE: 7.32%, ROCE: 20.00%, Dividend Yield: 0.44%, EPS: ₹7.96, Book Value: ₹54.44, Debt-to-Equity: 0.13, and Current Ratio: N/A. The company's market cap stands at ₹11,504.47 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

Question 7

How is Marksans Pharma Ltd stock performing today in the market?

Accepted Answer

Marksans Pharma Ltd stock opened at ₹253 and is currently trading at ₹256.7, showing a gain of ₹6.87 (2.75%). The intraday high is ₹260 and low is ₹252.1. The trading volume stands at 6,93,785 shares, indicating moderate market participation today.

Question 8

What is the P/E ratio of Marksans Pharma Ltd and what does it indicate?

Accepted Answer

Marksans Pharma Ltd has a Price-to-Earnings (P/E) ratio of 22.83, which means investors are willing to pay ₹22.83 for every ₹1 of earnings. With an EPS of ₹7.96, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.

Question 9

What is the market capitalization of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has a market capitalization of ₹11,504.47 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹256.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.

Question 10

What is the book value and P/B ratio of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has a book value of ₹54.44 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹256.7, which is 371.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.

Question 11

What is the ROE and ROCE of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has a Return on Equity (ROE) of 7.32% and Return on Capital Employed (ROCE) of 20.00%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.

Question 12

Which sector and industry does Marksans Pharma Ltd belong to?

Accepted Answer

Marksans Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.

Question 13

What is the debt-to-equity ratio of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has a debt-to-equity ratio of 0.13, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.

Question 14

What is the EPS (Earnings Per Share) of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has an Earnings Per Share (EPS) of ₹7.96, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹256.7 and P/E ratio of 22.83, investors are paying 22.83 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.

Question 15

What is the sales and profit growth of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.

Question 16

What is the current ratio of Marksans Pharma Ltd and what does it mean?

Accepted Answer

Marksans Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.

Question 17

How to analyze Marksans Pharma Ltd stock for investment?

Accepted Answer

To analyze Marksans Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (22.83), ROE (7.32%), debt-to-equity (0.13), and growth rates. 2) Technical Analysis - Check 52-week range (₹155.00 - ₹270.60), moving averages, and chart patterns. 3) Valuation - Compare current price (₹256.70) with book value (₹54.44) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.

Question 18

What is the face value of Marksans Pharma Ltd share?

Accepted Answer

The face value (or par value) of Marksans Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹256.7 is 25570x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.

Question 19

What are the risks of investing in Marksans Pharma Ltd stock?

Accepted Answer

Investing in Marksans Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹155.00 - ₹270.60). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.13 indicates leverage. 4) Liquidity Risk - Based on trading volume of 6,93,785 shares. 5) Valuation Risk - P/E of 22.83 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.

Question 20

How does Marksans Pharma Ltd compare with its industry peers?

Accepted Answer

Marksans Pharma Ltd operates in the industry with key metrics: P/E ratio of 22.83, ROE of 7.32%, market cap of ₹11,504.47 crores, and dividend yield of 0.44%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.13), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.

Question 21

What is the target price for Marksans Pharma Ltd stock?

Accepted Answer

Target prices for Marksans Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹256.7, with a 52-week range of ₹155.00 to ₹270.60. Based on fundamentals like P/E (22.83), ROE (7.32%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.

Question 22

When should I sell Marksans Pharma Ltd stock?

Accepted Answer

Consider selling Marksans Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹256.70. 2) Fundamental Deterioration - Declining ROE (currently 7.32%), increasing debt (D/E: 0.13), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.

Question 23

What are the tax implications of investing in Marksans Pharma Ltd stock?

Accepted Answer

Tax implications for Marksans Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.44%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.

Question 24

Is Marksans Pharma Ltd stock good for SIP (Systematic Investment Plan)?

Accepted Answer

Marksans Pharma Ltd can be considered for a Systematic Investment Plan (SIP) by long-term investors who want rupee-cost-averaging exposure to the sector sector. With a 52-week range of ₹155 to ₹270.6, monthly SIPs smooth out price volatility. Evaluate the company's ROE of 7.32%, profit growth of N/A% and debt-to-equity of 0.13 before committing — SIPs work best when underlying fundamentals are stable. Consult a SEBI-registered advisor for a personalised plan.

Question 25

When is the next dividend ex-date for Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd has a current dividend yield of 0.44% on a market price of ₹256.7. The next ex-dividend date is announced by the company through corporate filings on the BSE and NSE. Check the Corporate Actions section on this page for the most recent declared dividends, ex-dates, record dates and the full historical pay-out pattern.

Question 26

What is the latest shareholding pattern of Marksans Pharma Ltd?

Accepted Answer

Marksans Pharma Ltd's most recent quarterly shareholding pattern is displayed in the Ownership section above. It covers the promoter holding, foreign institutional investor (FII) stake, domestic institutional investor (DII) stake and public float — each tracked quarter-on-quarter so trends in institutional buying or selling are visible. Disclosed institutional holders are listed separately below the cohort breakdown.

Question 27

What are the support and resistance levels for Marksans Pharma Ltd stock?

Accepted Answer

Daily support and resistance levels for Marksans Pharma Ltd are computed live from the latest session's high (₹260), low (₹252.1) and close (₹256.7). They are listed in the Technicals section as classical pivot points (R1/R2/R3 above and S1/S2/S3 below the pivot) along with the Central Pivot Range (CPR) — useful reference levels for intraday and short-term traders.

Question 28

Has Marksans Pharma Ltd ever issued bonus shares or done a stock split?

Accepted Answer

The full history of Marksans Pharma Ltd bonus issues, stock splits and dividend declarations is in the Corporate Actions section above. Each event is listed with its announce date, record date and ratio, so investors can verify every capital-structure change Marksans Pharma Ltd has made over time on the NSE and BSE.

Question 29

How is Marksans Pharma Ltd performing compared to its sector and peers?

Accepted Answer

Marksans Pharma Ltd operates in the industry within the sector sector and trades at a P/E of 22.83 with an ROE of 7.32% and ROCE of 20.00%. Compare these to same-sector listed peers in the Peer Comparison section above to see whether Marksans Pharma Ltd is leading or lagging on valuation, capital efficiency and growth.

Question 30

What is the promoter holding in Marksans Pharma Ltd and is it increasing?

Accepted Answer

The latest promoter holding in Marksans Pharma Ltd is shown in the Ownership section, along with the quarter-on-quarter change in basis points. Rising promoter holding usually signals confidence in the business outlook, while sustained selling — especially by promoters who founded or run the company — is a signal worth investigating in the subsequent filings.

Question 31

Can I buy Marksans Pharma Ltd shares on NSE and BSE?

Accepted Answer

Yes — Marksans Pharma Ltd (MARKSANS) is listed and actively traded on both NSE and BSE. You can buy shares through any SEBI-registered stockbroker during market hours (09:15–15:30 IST on trading days). The current market price, today's intraday range and the live quote are at the top of this page; settlement is T+1 for Indian equities.

Level	Price (₹)	Distance	% Δ
R4	276.23	+19.53	+7.61%
R3	268.33	+11.63	+4.53%
R2	264.17	+7.47	+2.91%
R1	260.43	+3.73	+1.45%
PIVOT	256.27	-0.43	-0.17%
CURRENT	256.70	—	—
S1	236.73	-19.97	-7.78%
S2	244.63	-12.07	-4.70%
S3	248.37	-8.33	-3.25%
S4	252.53	-4.17	-1.62%

Marksans Pharma

Marksans Pharma Ltd valuation: P/E, P/B and sector benchmarks.

Valuation

Profitability

Growth

Financial Health

Marksans Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.

Marksans Pharma segment analysis: revenue and profit mix.

Segment-wise Financial Analysis

Marksans Pharma Ltd investment thesis: bull case, bear case, and the flip lines.

What you're getting.

What can break it.

What would change my mind.

Marksans shareholding pattern: promoters, FII, DII and public.

Shareholding Pattern

Marksans Pharma Ltd peer comparison — same-sector benchmarks.

Quick Compare

Peer Comparison

Marksans Pharma Ltd technical analysis: indicators, pivots and CPR.

Pivot points

Pivot levels · Classic

Marksans Pharma Ltd delivery volume — last 20 sessions of conviction.

Marksans Pharma announcements: results, concalls, ratings, M&A.

Marksans Pharma dividend history, splits and bonus issues.

About Marksans Pharma Ltd: business, sector, key facts.

Marksans Pharma Ltd

Questions investors ask about Marksans Pharma Ltd (MARKSANS).

Company Name
Aarey Drugs & Pharmaceuticals Ltd
Aarti Drugs Ltd
Aarti Pharmalabs Ltd
Ajanta Pharma Ltd
Akums Drugs & Pharmaceuticals Ltd
Albert David Ltd
Alivus Life Sciences Ltd
Alkem Laboratories Ltd
Alpa Laboratories Ltd
Amrutanjan Health Care Ltd
Alembic Pharmaceuticals Ltd
Astrazeneca Pharma India Ltd
Aurobindo Pharma Ltd
Bafna Pharmaceuticals Ltd
Bajaj Healthcare Ltd
Bal Pharma Ltd
Biocon Ltd
Biofil Chemicals & Pharmaceuticals Ltd
Bliss GVS Pharma Ltd
Blue Jet Healthcare Ltd
Brooks Laboratories Ltd
Caplin Point Laboratories Ltd
Cipla Ltd
Cohance Lifesciences Ltd
Concord Biotech Ltd
Dishman Carbogen Amcis Ltd
Divis Laboratories Ltd
Dr Reddys Laboratories Ltd
Emcure Pharmaceuticals Ltd
ERIS Lifesciences Ltd
FDC Ltd
Gland Pharma Ltd
Glaxosmithkline Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Granules India Ltd
Gufic BioSciences Ltd
Haleos Labs Limited
Hester Biosciences Ltd
Hikal Ltd
Indoco Remedies Ltd